Anthropic Ships Sonnet 5 With Agentic Safety and Pricing Details
1 July 20265 min read
Medicine
FDA Approves Relacorilant With Nab-Paclitaxel for Platinum-Resistant Ovarian Cancer
The FDA approved relacorilant with nab-paclitaxel for certain adults with platinum-resistant ovarian, fallopian tube or primary peritoneal cancer after prior systemic treatment.
Illustrative image. Cedar S. Insights uses editorial stock photography; images do not depict specific events described in articles.
The FDA approved relacorilant in combination with nab-paclitaxel on 25 March for adults with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer.
The indication covers patients who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab.
Relacorilant is a glucocorticoid receptor antagonist, making the approval notable because it pairs a hormone-signalling strategy with chemotherapy in a difficult ovarian-cancer setting.
Sourcing note: Indication, drug class and regimen details are from FDA. This article does not infer benefit beyond the approved population.
Why It Matters
Platinum-resistant ovarian cancer has limited options and poor outcomes. A new FDA-approved combination gives clinicians another tool, while the prior-treatment criteria show how tightly these approvals are defined.
Primary Sources
Our sourcing: Cedar S. Insights provides source-led editorial analysis. Reported company, institutional and regulatory claims are attributed to their original sources unless stated otherwise.
Corrections: If a material factual error is identified, Cedar S. Insights will update the relevant article and preserve the distinction between the corrected statement and supporting evidence.
Topics
FDARelacorilantOvarian CancerNab-PaclitaxelOncology